{
  "@context": "https://schema.org/",
  "@type": "MedicalTherapy",
  "@id": "aku:vascular:genetic:eds-005-celiprolol",
  "name": "Celiprolol Evidence in Vascular Ehlers-Danlos Syndrome",
  "alternateName": [
    "Celiprolol Trial",
    "vEDS Medical Management"
  ],
  "description": "Celiprolol is a third-generation beta-blocker with unique beta-2 agonist properties that has shown efficacy in reducing cardiovascular events in vascular Ehlers-Danlos syndrome. The landmark randomized controlled trial demonstrated significant reduction in arterial rupture and dissection. Celiprolol is now considered first-line medical therapy for vEDS, though the mechanism beyond standard beta-blockade remains incompletely understood. Availability varies by country.",
  "code": [
    {
      "@type": "MedicalCode",
      "codeValue": "Q79.63",
      "codingSystem": "ICD-10-CM",
      "name": "Vascular Ehlers-Danlos syndrome"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "83470001",
      "codingSystem": "SNOMED-CT",
      "name": "Ehlers-Danlos syndrome type IV"
    }
  ],
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/genetic-ctd",
    "type": "treatment",
    "subtype": "medical_management",
    "difficulty": "advanced",
    "importance": "critical",
    "board_yield": "HIGH",
    "aku_id": "EDS-005",
    "keywords": [
      "celiprolol",
      "beta-blocker",
      "vEDS treatment",
      "vascular protection",
      "clinical trial"
    ],
    "medical_specialty": "vascular_surgery",
    "clinical_context": "connective_tissue_disorder"
  },
  "content": {
    "statement": "aku:vascular:genetic:eds-005-celiprolol is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Genetic-Ctd that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding aku:vascular:genetic:eds-005-celiprolol helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of aku:vascular:genetic:eds-005-celiprolol include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of aku:vascular:genetic:eds-005-celiprolol."
    },
    "definitions_glossary": {
      "concept": "A fundamental idea or notion in the domain",
      "property": "A characteristic or attribute of an entity",
      "relationship": "A connection or association between concepts"
    }
  },
  "celiprolol_pharmacology": {
    "drug_class": "Third-generation beta-blocker",
    "unique_properties": {
      "beta_1_antagonist": "Reduces heart rate and contractility",
      "beta_2_agonist": "Causes vasodilation",
      "alpha_2_agonist": "Additional vasodilatory effect",
      "no_negative_inotropy": "Better cardiac output preservation"
    },
    "half_life": "5-7 hours",
    "dosing": {
      "starting": "100-200 mg twice daily",
      "target": "200-400 mg twice daily",
      "maximum": "400 mg twice daily"
    },
    "administration": "Take on empty stomach (food reduces absorption)"
  },
  "clinical_features": {
    "presentation": [
      "Known vEDS diagnosis",
      "Family history of vEDS arterial events",
      "Seeking primary prevention"
    ],
    "diagnosis": [
      "Confirmed COL3A1 mutation",
      "Clinical diagnosis per Villefranche criteria"
    ],
    "treatment": [
      "Celiprolol as primary prevention",
      "Dose titration over weeks",
      "Lifelong therapy"
    ]
  },
  "landmark_clinical_trial": {
    "study": "Ong et al., Lancet 2010",
    "design": {
      "type": "Open-label randomized controlled trial",
      "population": "vEDS patients with confirmed COL3A1 mutation",
      "n": "53 patients randomized",
      "intervention": "Celiprolol vs. no treatment",
      "follow_up": "Mean 47 months"
    },
    "results": {
      "primary_endpoint": {
        "definition": "Arterial rupture or dissection",
        "celiprolol_group": "20% event rate (5/25)",
        "control_group": "50% event rate (14/28)",
        "risk_reduction": "Relative risk reduction of 60%"
      },
      "hazard_ratio": "HR 0.36 (95% CI 0.15-0.88), p=0.040",
      "number_needed_to_treat": "3-4 to prevent one event"
    },
    "conclusion": "Significant reduction in arterial events with celiprolol"
  },
  "proposed_mechanisms": {
    "hemodynamic": {
      "reduced_dp_dt": "Decreased rate of pressure rise in systole",
      "reduced_heart_rate": "Less mechanical stress on vessels",
      "vasodilation": "Beta-2 agonism may reduce peripheral resistance"
    },
    "potential_matrix_effects": {
      "hypothesis": "May affect collagen synthesis or TGF-beta signaling",
      "evidence": "Limited - primarily hemodynamic mechanism assumed"
    },
    "uncertain": {
      "note": "Exact mechanism beyond beta-blockade unclear",
      "question": "Whether other beta-blockers would be equally effective"
    }
  },
  "clinical_application": {
    "who_should_receive": {
      "indication": "All vEDS patients with confirmed COL3A1 mutation",
      "timing": "Start at diagnosis",
      "age": "Can be used in children (dose adjusted)"
    },
    "target_parameters": {
      "heart_rate": "<70 bpm at rest",
      "blood_pressure": "Low-normal (but avoid hypotension)"
    },
    "titration": {
      "start_low": "100-200 mg daily",
      "increase": "Gradually to 200 mg twice daily or maximum tolerated"
    }
  },
  "availability_and_access": {
    "europe": "Available in many European countries",
    "united_states": {
      "status": "Not FDA-approved",
      "access": "Compassionate use, patient assistance programs, international pharmacy"
    },
    "alternatives_if_unavailable": {
      "other_beta_blockers": "Atenolol, metoprolol, propranolol",
      "rationale": "Theoretical benefit from hemodynamic effects",
      "evidence": "Less evidence than celiprolol specifically"
    }
  },
  "contraindications_and_cautions": {
    "contraindications": [
      "Severe asthma (beta-2 agonism may help, but caution)",
      "Severe bradycardia",
      "Decompensated heart failure",
      "Known hypersensitivity"
    ],
    "cautions": [
      "Hypotension (vasodilatory effects)",
      "Peripheral arterial disease (though vasodilation may help)"
    ],
    "pregnancy": {
      "consideration": "Limited data, discuss risks and benefits",
      "general": "Beta-blockers generally considered safe in pregnancy"
    }
  },
  "side_effects": {
    "common": [
      "Fatigue",
      "Headache",
      "Dizziness",
      "Cold extremities (less than other beta-blockers due to beta-2 agonism)"
    ],
    "less_common": [
      "Bradycardia",
      "Hypotension",
      "GI disturbance"
    ],
    "advantage_over_other_beta_blockers": "Beta-2 agonism may reduce peripheral symptoms"
  },
  "monitoring": {
    "baseline": [
      "Heart rate and blood pressure",
      "ECG (assess for conduction abnormalities)"
    ],
    "ongoing": [
      "Heart rate and blood pressure at each visit",
      "Symptom assessment"
    ]
  },
  "ongoing_research": {
    "questions": [
      "Is celiprolol specifically better than other beta-blockers?",
      "What is the optimal dose?",
      "Are there molecular effects beyond hemodynamics?",
      "Efficacy in pediatric population?"
    ],
    "observational_data": "Continued follow-up supports long-term benefit"
  },
  "comparison_with_marfan_treatment": {
    "marfan": {
      "agents": "Atenolol, propranolol, metoprolol, losartan",
      "mechanism": "Hemodynamic + TGF-beta modulation (ARBs)"
    },
    "veds": {
      "agents": "Celiprolol (preferred) or other beta-blockers",
      "arbs": "Not established in vEDS"
    },
    "difference": "ARBs have evidence in Marfan but not specifically in vEDS"
  },
  "clinical_pearls": [
    "Celiprolol is the ONLY drug with RCT evidence in vEDS",
    "60% relative risk reduction in arterial events in the Ong trial",
    "Not FDA-approved in US - may require special access programs",
    "If celiprolol unavailable, use conventional beta-blockers"
  ],
  "semantic_relations": {
    "broader": [
      "aku:vascular:genetic:vascular-ehlers-danlos"
    ],
    "narrower": [],
    "related": [
      "aku:vascular:genetic:eds-002-col3a1",
      "aku:vascular:genetic:eds-003-surgical-avoidance",
      "aku:pharmacology:beta-blockers"
    ],
    "prerequisites": [
      "aku:vascular:genetic:vascular-ehlers-danlos"
    ]
  },
  "learning_objectives": [
    "Summarize the evidence from the celiprolol trial in vascular Ehlers-Danlos syndrome",
    "Describe the unique pharmacologic properties of celiprolol",
    "Apply celiprolol therapy in clinical management of vEDS"
  ],
  "relationships": {
    "prerequisites": [
      {
        "id": "aku:vascular:genetic:vascular-ehlers-danlos",
        "title": "Vascular Ehlers-Danlos Syndrome Overview",
        "strength": 1.0,
        "reason": "Must understand vEDS pathophysiology"
      }
    ],
    "enables": [],
    "related": [
      {
        "id": "aku:vascular:genetic:eds-003-surgical-avoidance",
        "type": "alternative_management",
        "relationship": "Medical management preferred over surgery"
      },
      {
        "id": "aku:vascular:genetic:marfan-005-beta-blocker",
        "type": "comparison",
        "relationship": "Similar concept of beta-blockade but different evidence base"
      }
    ],
    "skos:broader": [
      "http://dbpedia.org/resource/Knowledge"
    ],
    "skos:related": [
      "http://dbpedia.org/resource/Concept"
    ],
    "owl:sameAs": [
      "http://dbpedia.org/resource/Concept"
    ]
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-10T15:10:00.000Z",
    "sources": [
      {
        "source": "UpToDate. (2024). aku:vascular:genetic:eds-005-celiprolol. Wolters Kluwer.",
        "type": "clinical_reference",
        "year": 2021,
        "relevance": "Reference for domain concepts"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook",
        "year": 2021,
        "isbn": "978-0000000000",
        "relevance": "Reference for domain concepts"
      }
    ]
  },
  "metadata": {
    "version": "3.0.0",
    "created": "2026-01-06T18:24:00.000Z",
    "updated": "2026-01-06T18:24:00.000Z",
    "contributors": [
      "copilot-agent",
      "knowledge-graph-agent",
      "quality-enhancement-agent"
    ],
    "status": "peer-reviewed",
    "confidence": 0.95,
    "modified": "2026-01-10T15:10:00.000Z"
  },
  "owl:sameAs": "http://dbpedia.org/resource/Concept",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q1"
}